Ionis Pharmaceuticals, Inc. - Common Stock (IONS)
Frequently Asked Questions About Ionis Pharmaceuticals, Inc. - Common Stock (IONS)
Has Ionis Pharmaceuticals received any awards?
Ionis Pharmaceuticals has received multiple awards for its contributions to biotechnology and drug development, including recognition for its innovative pipeline and commitment to addressing rare genetic diseases. The company's advancement of antisense technology has also been acknowledged as a significant achievement in transformative medicine.
How can I invest in Ionis Pharmaceuticals?
To invest in Ionis Pharmaceuticals, individuals can purchase shares through any registered brokerage firm that provides access to the Nasdaq stock exchange where Ionis trades under the ticker symbol 'IONS'. Investors should conduct their research, consider their financial goals, and consult with financial experts before making investment decisions.
How does Ionis Pharmaceuticals ensure compliance with regulations?
Ionis Pharmaceuticals adheres to strict regulatory requirements set forth by health authorities, including the FDA. The company implements comprehensive quality systems and processes to ensure compliance with Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and other regulations to safeguard patients and maintain product integrity.
Is Ionis Pharmaceuticals publicly traded?
Yes, Ionis Pharmaceuticals is publicly traded on the Nasdaq stock exchange under the ticker symbol 'IONS'. The company went public in 1991 and has since been involved in active research and development efforts in the biotechnology arena.
What are some key products developed by Ionis Pharmaceuticals?
Some key products developed by Ionis Pharmaceuticals include Spinraza (nusinersen), which is used to treat spinal muscular atrophy (SMA), and Tegsedi (inotersen), approved for the treatment of hereditary ATTR amyloidosis. These products reflect the company's commitment to addressing serious health conditions with unmet medical needs.
What are the company's financials like?
Ionis Pharmaceuticals has demonstrated a solid financial performance, with a diverse revenue stream stemming from product sales, collaborations, and licensing agreements. The company's financial health is bolstered by the success of approved products like Spinraza and increasing investments in their expanding pipeline, which continues to attract interest from investors.
What does Ionis Pharmaceuticals, Inc. do?
Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in drug discovery and development, primarily focusing on treatments for rare diseases and conditions caused by genetic mutations. They utilize their proprietary antisense technology to develop therapies that target and modify RNA, which can lead to the production of therapeutic proteins or the reduction of harmful proteins.
What is antisense technology?
Antisense technology is a method used in biotechnology where short, synthetic strands of nucleic acids are designed to bind to specific RNA molecules. This binding can inhibit the translation of harmful proteins or promote the production of beneficial proteins, making it an innovative approach to treating genetic disorders.
What is Ionis Pharmaceuticals' approach to research and development?
Ionis Pharmaceuticals adopts a rigorous approach to research and development, focusing on innovation, collaboration, and excellence in science. Their R&D process emphasizes early-stage discovery and strategic partnerships, allowing them to explore broad therapeutic possibilities while efficiently advancing promising candidates through clinical trials.
What is the company's approach to sustainability?
Ionis Pharmaceuticals is committed to sustainability and corporate responsibility by engaging in practices that promote environmental stewardship, workplace safety, and community engagement. The company aims to minimize its ecological footprint while contributing positively to the health and well-being of society.
What is the company's pipeline focused on?
Ionis Pharmaceuticals has a diverse pipeline focused primarily on therapies for neurological diseases, cardiovascular diseases, metabolic diseases, and rare genetic disorders. Their research aims to develop innovative treatments that can provide significant clinical benefits to patients suffering from these conditions.
What is the company's vision?
Ionis Pharmaceuticals' vision is to become a global leader in RNA-targeted therapies, transforming the treatment landscape for patients with serious diseases. They aim to leverage their proprietary technology to develop effective, innovative solutions that can address unmet medical needs while delivering significant clinical benefits.
What is the significance of Spinraza?
Spinraza (nusinersen) is significant as it was the first-ever FDA-approved treatment for spinal muscular atrophy (SMA), a severe genetic disorder that leads to muscle weakness and atrophy. Its approval in 2016 marked a groundbreaking moment in the field of neurology and demonstrated the potential of antisense oligonucleotide therapies.
What recent developments has Ionis Pharmaceuticals announced?
Ionis Pharmaceuticals regularly announces advancements related to their pipeline, collaborations, and research initiatives. Recent developments might include updates on clinical trial results, new partnerships, or FDA approvals for their investigational therapies. For the latest announcements, checking their investor relations page is advisable.
What role does clinical trials play in Ionis Pharmaceuticals?
Clinical trials are essential to Ionis Pharmaceuticals' research and development process. They conduct rigorous clinical studies to evaluate the safety and efficacy of their drug candidates, gathering critical data that informs the regulatory approval process and ultimately leads to the development of new therapies for patients.
When was Ionis Pharmaceuticals founded?
Ionis Pharmaceuticals was founded in 1989. Originally established as Isis Pharmaceuticals, the company underwent a rebranding in 2015 to reflect its focus on RNA-targeted therapies and its broader pipeline of therapeutic products.
Where is Ionis Pharmaceuticals based?
Ionis Pharmaceuticals is headquartered in Carlsbad, California. The company's location in this biotech hub allows it to collaborate with various pharmaceutical and biotechnology companies and access key resources for research and development.
Who are Ionis Pharmaceuticals' key partners?
Ionis Pharmaceuticals has established partnerships with several major pharmaceutical companies, including Biogen, AstraZeneca, and Roche. These collaborations enable the company to leverage additional resources and expertise, accelerating the development of therapies and facilitating the commercialization of their products.
Who are the key executives at Ionis Pharmaceuticals?
Ionis Pharmaceuticals' executive team includes key figures such as CEO and co-founder Stanley T. Crooke, who has been integral in the company’s direction and scientific innovation. The leadership team consists of experienced professionals from the biotechnology and pharmaceutical industries, committed to advancing the company’s mission.
What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 28.71
When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 4.07B
How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
Ionis Pharmaceuticals, Inc. - Common Stock has 141.80M shares outstanding.